Central to their discovery is the identification of a complex reprogramming of neutrophils—white blood cells that serve as primary responders in the innate immune system—within the tumor microenvironment of bone metastases. Unlike their typical mature counterparts that aid in attacking tumors, these neutrophils are converted into an immature, immunosuppressive state. This altered functional phenotype, the researchers report in the exacting pages of Cancer Cell, severely blunts the anti-tumor immune response. The culprit behind this neutrophil reprogramming is a protein called Dickkopf-related protein 1 (DKK1), which is abundantly produced by the bone tumor niche.

DKK1, previously implicated in bone biology and cancer progression, acts as a molecular architect that remodels the cellular landscape to favor tumor persistence. Through a sophisticated series of biochemical signals, DKK1 disrupts neutrophil maturation, which consequently fosters a tumor-friendly microenvironment. This aberrant state is marked by the production of another molecule, chitinase 3-like 3 (CHI3L3), which exerts potent suppressive effects on cytotoxic CD8+ T cells—the main warriors of the adaptive immune system tasked with identifying and destroying malignant cells.

Previous research has shown neutrophils to be ambivalent players in cancer biology, with their role oscillating between tumor promotion and tumor suppression depending on their specific activation states. The Merghoub and Shi study crucially emphasizes that it is the immature, DKK1-reprogrammed neutrophils that dominate within bone metastases, effectively erecting an immunological shield that thwarts therapies designed to unleash T cell-mediated killing. This insight elucidates a pivotal reason why immune checkpoint blockade therapies, such as anti-PD-1 antibodies, fail to produce significant responses in patients whose cancers have metastasized to the bone.

In meticulously designed mouse models of triple-negative breast cancer metastatic to bone, the researchers demonstrated that blocking DKK1 with a targeted antibody markedly reversed this immune suppression. This intervention allowed neutrophils to mature appropriately, reducing CHI3L3 levels and relieving the inhibition on CD8+ T cells. Remarkably, when DKK1 blockade was combined with immune checkpoint inhibitors, tumors regressed dramatically, with some completely eradicated. These findings provide compelling preclinical evidence that DKK1-targeted therapies could synergize with existing immunotherapies to overcome resistance in bone metastases, a dire unmet clinical need.

Expanding beyond preclinical models, their analyses included patient-derived serum samples from individuals with gastric cancer and bone metastases, where elevated DKK1 levels mirrored those observed in experimental contexts. This translational aspect not only reinforces the relevance of their findings to human disease but also suggests potential biomarkers—DKK1 and CHI3L3—that could stratify patients likely to benefit from combined immunotherapeutic approaches targeting both neutrophils and T cells.

From a mechanistic standpoint, the study delved deep into the intracellular signaling pathways activated by DKK1 that orchestrate neutrophil dysfunction. By pinpointing these molecular conduits, the research identifies multiple potential pharmacological targets beyond DKK1 itself, broadening the horizon for drug development aiming to recalibrate the immune microenvironment in metastatic bone lesions.

This research further challenges the established focus on targeting adaptive immunity alone, emphasizing the critical role of innate immune cells—particularly neutrophils—in shaping therapeutic outcomes. The data argue for an integrated immunotherapeutic strategy that not only reinvigorates T cells but simultaneously reprograms neutrophils away from a suppressive phenotype, thus unleashing a coordinated immune assault on cancer.

The clinical implications are especially promising, given that DKN-01, a DKK1-blocking antibody, is already in clinical trials, accelerating the potential translation of these discoveries into effective treatments. The identification of CHI3L3 and its gene expression signatures as biomarkers opens avenues for precision medicine, enabling oncologists to tailor therapies according to the immune landscape of individual tumors.

The broader significance of this study lies in its illumination of the complex interplay between cancer cells and their microenvironment, specifically within the unique immunosuppressive context of bone metastases. By unveiling the molecular and cellular underpinnings of immunotherapy resistance, this work not only advances our understanding of cancer biology but also offers a tangible path toward improving outcomes for patients grappling with metastatic disease, for whom therapeutic options remain woefully inadequate.

In summation, this rigorous investigation by Merghoub, Shi, and colleagues delineates a novel immunosuppressive axis driven by DKK1-induced neutrophil immaturity within bone metastases. Intervening in this axis restores immune competency, sensitizes tumors to checkpoint blockade, and presents a compelling target for next-generation cancer immunotherapies. Their findings herald a paradigm shift, advocating for the co-targeting of innate and adaptive immunity in combating metastatic cancer, with a profound potential to reshape clinical practice and patient survival.

Subject of Research: Neutrophil reprogramming and immunotherapy resistance in bone metastases mediated by DKK1.

Article Title: DKK1-mediated neutrophil reprogramming fosters immunotherapy resistance in bone metastases.

News Publication Date: August 7, 2025.

Web References:

• Cancer Cell article: https://www.sciencedirect.com/science/article/abs/pii/S1535610825003137?via%3Dihub
• Related neutrophil study: https://www.nature.com/articles/s41422-025-01145-0

Image Credits: Ludwig Cancer Research, image of Taha Merghoub.

Keywords: Health and medicine, Cancer, Immunotherapy, Neutrophils, Bone metastases, DKK1, Tumor microenvironment, CD8+ T cells, Innate immunity, Immune checkpoint blockade.

METex14 mutations represent a distinct oncogenic driver in non-small-cell lung cancer (NSCLC) and have garnered significant attention due to their actionable potential. These mutations lead to skipping of exon 14, which encodes a juxtamembrane domain important for MET degradation, resulting in sustained receptor activation and oncogenic signaling. The identification of METex14 mutations has paved the way for the development and approval of targeted therapies such as MET tyrosine kinase inhibitors (TKIs), including capmatinib, tepotinib, and savolitinib, which have demonstrated substantial efficacy in advanced NSCLC harboring these alterations.

Beyond METex14, MET gene amplification and protein overexpression occur more frequently across various tumor types and are especially prominent as mechanisms of acquired resistance in cancers initially driven by other oncogenic alterations. The amplification and overexpression of MET amplify downstream signaling pathways that promote tumor cell proliferation, survival, migration, and invasion. Clinically, MET amplification and overexpression often predict sensitivity to MET-targeted therapies, although the heterogeneity of these alterations poses challenges in patient stratification and treatment optimization.

The treatment landscape for MET-altered cancers is rapidly evolving, moving beyond classical TKIs towards a diversified arsenal of therapeutic agents. Emerging evidence supports the efficacy of novel modalities including anti-MET monoclonal antibodies, bispecific antibodies, and MET-directed antibody–drug conjugates (ADCs). These agents offer alternative mechanisms to disrupt MET signaling, binding extracellular domains or delivering cytotoxic payloads specifically to MET-expressing tumor cells. This multifaceted approach aims to circumvent resistance mechanisms and improve clinical outcomes, especially in patients with resistance to TKIs or those whose tumors exhibit MET overexpression rather than mutation.

A landmark advancement in this therapeutic expansion occurred in May 2025 with the U.S. Food and Drug Administration (FDA) approval of telisotuzumab vedotin, a MET-directed ADC indicated for patients with previously treated advanced-stage nonsquamous NSCLC exhibiting high MET expression (≥50% of tumor cells with 3+ immunohistochemical staining). This ADC combines a monoclonal antibody targeting MET with a microtubule inhibitor payload, harnessing selective delivery of chemotherapy to MET-overexpressing cells, thereby minimizing systemic toxicity and enhancing antitumor activity.

Understanding the distinct adverse event profiles associated with various MET-directed therapies is becoming increasingly important in clinical practice. For MET TKIs, common toxicities include peripheral edema, nausea, and elevated liver enzymes, reflecting the on-target effects of MET inhibition in normal tissues. Conversely, MET-directed ADCs share toxicity characteristics with other conjugates, such as hematologic suppression and neuropathy, arising from the payload component. Early recognition and management of these toxicities are critical to maintain treatment adherence and optimize therapeutic benefit.

The heterogeneity of MET alterations among solid tumors necessitates robust diagnostic strategies to accurately identify patients who may benefit from MET-targeted therapies. Techniques such as next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), and immunohistochemistry (IHC) are employed to detect METex14 mutations, gene amplifications, and protein overexpression, respectively. The integration of these assays into routine diagnostics expedites patient selection, ensuring personalized approaches that align with the molecular landscape of the tumor.

Crucially, MET alterations are not restricted to NSCLC but extend to other malignancies, including gastric, colorectal, hepatocellular carcinoma, and glioblastoma, albeit at varying frequencies. This broad distribution implies that therapeutic strategies targeting MET could transcend lung cancer, offering new hope for patients with MET-driven tumors in diverse anatomical and molecular contexts. Current investigations are exploring the efficacy of MET inhibitors and ADCs across these cancer types, aiming to expand the therapeutic arsenal beyond its current indications.

Resistance mechanisms to MET-targeted therapies present another formidable hurdle in clinical management. Tumor cells may acquire secondary mutations in MET that diminish TKI binding or activate alternative signaling pathways, undermining treatment efficacy over time. Combination strategies pairing MET inhibitors with agents targeting parallel pathways or immune checkpoint inhibitors are under active investigation to overcome resistance and sustain durable responses.

From a molecular standpoint, MET functions as a receptor tyrosine kinase that binds hepatocyte growth factor (HGF), initiating signaling cascades such as RAS-RAF-MEK-ERK and PI3K-AKT-mTOR, which regulate cellular proliferation, survival, and motility. Alterations that lead to constitutive MET activation hijack these pathways, fostering oncogenesis. Targeted inhibition disrupts this pathogenic signaling, reaffirming the vital role of MET in cancer biology and its promise as a therapeutic target.

The dynamic interplay between MET-driven oncogenesis and the tumor microenvironment also merits attention. MET signaling contributes to angiogenesis and modulates immune cell infiltration, factors that influence tumor progression and response to therapy. Innovative treatment paradigms combining MET-targeted agents with anti-angiogenic drugs or immunotherapies may exploit these interactions to enhance clinical efficacy.

In summary, the therapeutic targeting of MET has transitioned from a niche focus in lung cancer to a burgeoning frontier across multiple solid tumors. Advances in molecular diagnostics, novel drug modalities, and an expanding understanding of resistance mechanisms collectively inform a more nuanced approach to MET-altered cancers. As the clinical toolbox grows, the challenge will be to tailor therapies based on the specific MET alteration and tumor context, maximizing patient benefit while minimizing toxicity.

Looking forward, ongoing clinical trials and translational research continue to illuminate the complexities of MET biology and its therapeutic vulnerabilities. Real-world evidence will be indispensable in refining patient selection criteria, optimizing combination regimens, and managing adverse events. The ultimate goal remains to harness the full potential of MET targeting, transforming outcomes for patients with MET-driven malignancies across oncology.

The approval of telisotuzumab vedotin represents both a milestone and a catalyst in the field of MET-directed therapeutics. Its success exemplifies how antibody–drug conjugates can effectively exploit overexpressed oncoproteins to deliver precise cytotoxic therapy. This model is likely to inspire further innovations, including next-generation ADCs and bispecific constructs, broadening the scope of MET-targeted interventions.

With the expanding array of MET-directed interventions, clinicians and researchers must remain vigilant to the nuances of each therapeutic class. Comprehensive assessment of pharmacodynamics, resistance patterns, and toxicity profiles will inform rational sequencing and combination strategies. Such multidimensional approaches promise to elevate the standard of care for patients harboring MET alterations beyond current paradigms.

In conclusion, MET’s evolving role as a therapeutic target underscores the convergence of molecular oncology, drug development, and clinical innovation. The insights gleaned thus far embolden ongoing efforts to integrate MET-targeting agents into personalized cancer treatment frameworks, heralding a new era in the management of NSCLC and a spectrum of other solid tumors where MET aberrations are paramount.

Subject of Research: Therapeutic targeting of MET alterations in non-small-cell lung cancer (NSCLC) and other solid tumors

Article Title: Evolving roles of MET as a therapeutic target in NSCLC and beyond

Article References:

Lee, J.B., Shim, J.S. & Cho, B.C. Evolving roles of MET as a therapeutic target in NSCLC and beyond.
Nat Rev Clin Oncol (2025). https://doi.org/10.1038/s41571-025-01051-9

Image Credits: AI Generated